US EditionA Clinical Trial Demonstrates the Efficacy of Targeted Therapy Against an Ultra Rare Tumor
3 Articles
3 Articles
A clinical trial with the participation of the Vall d'Hebron Institute of Oncology (Vhio) of Barcelona has demonstrated the efficacy of a therapy directed with the drug pimicotinib in patients with tumor of giant tendinous sheath cells (TGCT), considered ultra rare, since less than one case has been detected for every million inhabitants per year.The results, published this Friday in the journal The Lancet, have led the regulatory authorities to…
The results of this study, in which Dr. César Serrano, a medical oncologist at the Vall d’Hebron University Hospital and head of the Translational Research Group in Sarcomas del VHIO, participated, were presented at the last Congress of the American Society of Medical Oncology (ASCO) and are published today in the journal The Lancet. “TGCT is an ultrarrheal tumor of very rare, locally aggressive mesenchymal origin that affects the joints and is …
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
